SGHT Stock Overview
An ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sight Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.15 |
| 52 Week High | US$9.31 |
| 52 Week Low | US$1.04 |
| Beta | 2.72 |
| 1 Month Change | 22.85% |
| 3 Month Change | 55.43% |
| 1 Year Change | -10.51% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -78.66% |
Recent News & Updates
Recent updates
Sight Sciences, Inc. (NASDAQ:SGHT) Stock Catapults 46% Though Its Price And Business Still Lag The Industry
Dec 19
Some Analysts Just Cut Their Sight Sciences, Inc. (NASDAQ:SGHT) Estimates
Nov 19Sight Sciences Grows Portfolio Amid Reimbursement Pressure
Aug 19Sizing Up Sight Sciences
Jun 26Sight Sciences - Opening My Eyes
Apr 08Analysts Have Been Trimming Their Sight Sciences, Inc. (NASDAQ:SGHT) Price Target After Its Latest Report
Mar 26Sight Sciences: Appeal Is Visually Increasing
Jan 13Shareholder Returns
| SGHT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 13.1% | 1.6% | 1.4% |
| 1Y | -10.5% | 4.4% | 23.1% |
Return vs Industry: SGHT underperformed the US Medical Equipment industry which returned 3% over the past year.
Return vs Market: SGHT underperformed the US Market which returned 21.7% over the past year.
Price Volatility
| SGHT volatility | |
|---|---|
| SGHT Average Weekly Movement | 9.6% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SGHT's share price has been volatile over the past 3 months.
Volatility Over Time: SGHT's weekly volatility has decreased from 18% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 214 | Paul Badawi | www.sightsciences.com |
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company’s products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Sight Sciences, Inc. Fundamentals Summary
| SGHT fundamental statistics | |
|---|---|
| Market cap | US$351.78m |
| Earnings (TTM) | -US$54.75m |
| Revenue (TTM) | US$81.50m |
4.4x
P/S Ratio-6.5x
P/E RatioIs SGHT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGHT income statement (TTM) | |
|---|---|
| Revenue | US$81.50m |
| Cost of Revenue | US$11.63m |
| Gross Profit | US$69.87m |
| Other Expenses | US$124.62m |
| Earnings | -US$54.75m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 85.73% |
| Net Profit Margin | -67.18% |
| Debt/Equity Ratio | 30.9% |
How did SGHT perform over the long term?
See historical performance and comparison